ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Health Canada has ...

Anti-VEGF injections may improve visual outcomes in patients with diabetic macular edema who have vitreomacular adhesions, according to a substudy of READ-3. “VMA does not adversely influence ...

A single intravitreal injection of a biologic agent effectively resolved vitreomacular traction and closed macular holes without surgery, according to a study. Perspective from Pravin U. Dugel, MD ...

To study the efficacy of a single intravitreal injection of expansile gas as a valuable alternative to current treatment options (conservative, pharmacological, and surgical) in patients with ...

Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole One-time intravitreal injection of Jetrea has shown efficacy in the ...

Over the past two decades, the role of vitreomacular adhesion in vitreomacular interface pathologies, such as vitreomacular traction syndrome, epiretinal membrane and macular hole, has been ...

The clinical implications of this study are important for physicians and their patients. Vitrectomy has traditionally been the only treatment for vitreomacular traction and macular holes, but it is ...

ThromboGenics announced data from two Phase 3 clinical trials evaluating ocriplasmin for the treatment of vitreomacular traction (VMT) and macular holes. The studies highlight that a single ...

ThromboGenics NV (euronext brussels:THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic ...

Stalmans et al. (Aug. 16 issue) 1 report that intravitreal injection of ocriplasmin was superior to injection of placebo in altering the vitreoretinal interface of affected eyes. It was associated ...